ReviewJournal of thrombosis and thrombolysis2016
Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism.
Review in Journal of thrombosis and thrombolysis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 87 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Inpatient Monitoring of Unfractionated Heparin
Optimization of Intravenous Unfractionated Heparin Starting Infusion Rate for Adult Patients With Deep Vein Thrombosis/Pulmonary Embolism or Cardiac Indications
Who cites it
87 citing papers in PubMed, 5 syntheses or guidelines pooled it, 224 citations in OpenAlex.
- Guideline
- ISTH DIC subcommittee communication on anticoagulation in COVID-19.Journal of thrombosis and haemostasis : JTH · 2020Guideline
- Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients.European journal of clinical pharmacology · 2019Pooled it
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.Blood advances · 2018Guideline
- Pooled it
- Engineering Host-Guest Interactions for Next-Generation Heparin Biosensors.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Comparative Analysis of Anticoagulation Stability in Critically Ill Patients Receiving Argatroban for Suspected or Confirmed Heparin-Induced Thrombocytopenia Compared with Unfractionated Heparin: A Retrospective Cohort Study.Hematology reports · 2026Article
- Viscoelastic point-of-care testing for monitoring unfractionated heparin in critically ill patients: a prospective observational study comparing ClotPro® IN/HI-Test, aPTT and Anti-Xa activity.BMC anesthesiology · 2026Observational
- Heparin Anticoagulant Therapy and Its Monitoring.Biomolecules · 2026Review
- Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Physiologically Adaptive Soft Millirobot for Atraumatic Endovascular Therapy.Advanced functional materials · 2026Article
- Article
- Treatment failure in patients with obesity with venous thromboembolism receiving truncated vs. recommended lead-in times with apixaban at an academic medical center.Journal of thrombosis and thrombolysis · 2026Article
- Tissue regenerative potential of human dental pulp mesenchymal stem cell conditioned medium in wound healing of the medicinal leech.Stem cell research & therapy · 2025Article
- Physiologically Adaptive Soft Millirobot for Atraumatic, Image-Guided Endovascular Therapy.Research square · 2025Article
- Heparin resistance in a patient with severe acute pancreatitis: a case report.Laboratory medicine · 2025Article
- Comparative Safety of Anticoagulant, Antiplatelet and the Combination of Both for Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.Biomedicines · 2025Review
- Stem Cell Therapy Approaches for Ischemia: Assessing Current Innovations and Future Directions.International journal of molecular sciences · 2025Review
- A comparison of the optical method with the mechanical method in routine coagulation tests.Journal of medical biochemistry · 2025Article
- Evaluation of unfractionated heparin dosing using an antifactor-Xa-based protocol in non-obese vs. obese patients for acute venous thromboembolism.Journal of thrombosis and thrombolysis · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is a serious and often fatal medical condition with an increasing incidence. Despite the changing landscape of VTE treatment with the introduction of the new direct oral anticoagulants many uncertainties remain regarding the optimal use of traditional parenteral agents. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. This specific chapter addresses the practical management of heparins including low molecular weight heparins and fondaparinux. For each anticoagulant a list of the most common practice related questions were created. Each question was addressed using a brief focused literature review followed by a multidisciplinary consensus guidance recommendation. Issues addressed included initial anticoagulant dosing recommendations, recommended baseline laboratory monitoring, managing dose adjustments, evidence to support a relationship between laboratory tests and meaningful clinical outcomes, special patient populations including extremes of weight and renal impairment, duration of necessary parenteral therapy during the transition to oral therapy, candidates for outpatient treatment where appropriate and management of over-anticoagulation and adverse effects including bleeding and heparin induced thrombocytopenia. This article concludes with a concise table of clinical management questions and guidance recommendations to provide a quick reference for the practical management of heparin, low molecular weight heparin and fondaparinux.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.